Literature DB >> 15607957

Oncogene addiction: sometimes a temporary slavery.

Jos Jonkers1, Anton Berns.   

Abstract

Tumors induced in conditional oncomice can show remarkable different responses to subsequent oncogene deprivation. Complete sustained regression, concomitant with massive differentiation and/or apoptosis, and partial regression are both observed. In the latter case, tumor growth either resumes without being dependent any longer on the oncogene, or requires reactivation of the oncogene in cells that have become dormant. These models reflect many of the features we also witness in human cancer and can therefore assist us in understanding the underlying mechanisms and in designing more effective treatment protocols.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15607957     DOI: 10.1016/j.ccr.2004.12.002

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  47 in total

1.  Depot formation of doxycycline impairs Tet-regulated gene expression in vivo.

Authors:  Kathleen Anders; Christian Buschow; Jehad Charo; Thomas Blankenstein
Journal:  Transgenic Res       Date:  2011-12-14       Impact factor: 2.788

Review 2.  Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs.

Authors:  Xiangyi Lu; Li Xiao; Luan Wang; Douglas M Ruden
Journal:  Biochem Pharmacol       Date:  2011-11-22       Impact factor: 5.858

Review 3.  Nanoparticles: a promising modality in the treatment of sarcomas.

Authors:  Michiro Susa; Lara Milane; Mansoor M Amiji; Francis J Hornicek; Zhenfeng Duan
Journal:  Pharm Res       Date:  2010-05-27       Impact factor: 4.200

Review 4.  [Basics of molecular diagnostics and therapy of malignant tumors].

Authors:  P T Daniel; B Dörken
Journal:  Internist (Berl)       Date:  2005-08       Impact factor: 0.743

5.  The GAP-related domain of neurofibromin attenuates proliferation and downregulates N- and K-Ras activation in Nf1-negative AML cells.

Authors:  Kelly J Morgan; Matthew A Rowley; Stephen M Wiesner; Diane E Hasz; Brian Van Ness; David A Largaespada
Journal:  Leuk Res       Date:  2007-01-12       Impact factor: 3.156

6.  T-ALL can evolve to oncogene independence.

Authors:  Hesham Abdulla; Anh Vo; Benjamin J Shields; Tenae J Davies; Jacob T Jackson; Raed Alserihi; Elizabeth M Viney; Tin Wong; Feng Yan; Nicholas C Wong; Lisa Demoen; David J Curtis; Warren S Alexander; Pieter Van Vlierberghe; Ross A Dickins; Matthew P McCormack
Journal:  Leukemia       Date:  2021-01-22       Impact factor: 11.528

7.  Loss of p53 impedes the antileukemic response to BCR-ABL inhibition.

Authors:  Hans-Guido Wendel; Elisa de Stanchina; Enriqué Cepero; Sagarika Ray; Michael Emig; Jordan S Fridman; Darren R Veach; William G Bornmann; Bayard Clarkson; W Richard McCombie; Scott C Kogan; Andreas Hochhaus; Scott W Lowe
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

8.  RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia.

Authors:  Won-Il Kim; Ilze Matise; Miechaleen D Diers; David A Largaespada
Journal:  Blood       Date:  2008-10-24       Impact factor: 22.113

9.  A critical role for choline kinase-alpha in the aggressiveness of bladder carcinomas.

Authors:  E Hernando; J Sarmentero-Estrada; T Koppie; C Belda-Iniesta; V Ramírez de Molina; P Cejas; C Ozu; C Le; J J Sánchez; M González-Barón; J Koutcher; C Cordón-Cardó; B H Bochner; J C Lacal; A Ramírez de Molina
Journal:  Oncogene       Date:  2009-05-18       Impact factor: 9.867

10.  Targeting ceramide synthase 6-dependent metastasis-prone phenotype in lung cancer cells.

Authors:  Motoshi Suzuki; Ke Cao; Seiichi Kato; Yuji Komizu; Naoki Mizutani; Kouji Tanaka; Chinatsu Arima; Mei Chee Tai; Kiyoshi Yanagisawa; Norie Togawa; Takahiro Shiraishi; Noriyasu Usami; Tetsuo Taniguchi; Takayuki Fukui; Kohei Yokoi; Keiko Wakahara; Yoshinori Hasegawa; Yukiko Mizutani; Yasuyuki Igarashi; Jin-ichi Inokuchi; Soichiro Iwaki; Satoshi Fujii; Akira Satou; Yoko Matsumoto; Ryuichi Ueoka; Keiko Tamiya-Koizumi; Takashi Murate; Mitsuhiro Nakamura; Mamoru Kyogashima; Takashi Takahashi
Journal:  J Clin Invest       Date:  2015-12-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.